Evidence map›Paper›PMID 39967218›Full record

ArticleJACC. Asia2025

Effect of Renal Impairment on Clinical Outcomes After Mitral Valve Transcatheter Edge-to-Edge Repair.

Kazuki Tanaka, Junichi Yamaguchi, Masafumi Yoshikawa, Eiji Shibahashi, Hisao Otsuki, Takanori Kawamoto, Chihiro Koyanagi, Yusuke Inagaki, Tomohito Kogure, Masanori Yamamoto and 21 more

Abstract read
In one paragraph

Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Renal resistive index for risk stratification and functional evaluation after transcatheter mitral valve repair: the ReRISE study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Kazuki TanakaDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Junichi YamaguchiDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan. Electronic address: j.yamaguchi0110@gmail.com.
Masafumi YoshikawaDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Eiji ShibahashiDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Hisao OtsukiDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Takanori KawamotoDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Chihiro KoyanagiDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Yusuke InagakiDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Tomohito KogureDepartment of Cardiology Tokyo Woman's Medical University, Tokyo, Japan.
Masanori YamamotoDepartment of Cardiology, Toyohashi Heart Center, Toyohashi, Japan; Department of Cardiology, Nagoya Heart Center, Nagoya, Japan; Department of Cardiology, Gifu Heart Center, Gifu, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Okayama, Japan; Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Faculty of Medicine, Tokyo, Japan.
Masahiko AsamiDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Masaki NakashimaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Yusuke EntaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.
Shinichi ShiraiDivision of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Masaki IzumoDivision of Cardiology, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Shingo MizunoDepartment of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan.
Yusuke WatanabeDepartment of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Makoto AmakiDepartment of Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Kazuhisa KodamaDivision of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Shunsuke KuboDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Yoshifumi NakajimaDivision of Cardiology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Toru NaganumaDepartment of Cardiology, New Tokyo Hospital, Chiba, Japan.
Hiroki BotaDepartment of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Yohei OhnoDepartment of Cardiology, Tokai University School of Medicine, Isehara, Japan.
Masahiro YamawakiSaiseikai Yokohama City Eastern Hospital, Kanagawa, Japan.
Hiroshi UenoSecond Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kazuki MizutaniDivision of Cardiology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
OCEAN-Mitral Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal impairment is associated with poor clinical outcomes in patients with cardiovascular diseases. Some studies have revealed the impact of renal impairment on the clinical outcomes of patients who underwent mitral valve transcatheter edge-to-edge repair (M-TEER). However, limited data are available regarding the impact of baseline renal impairment after M-TEER in Asian-Pacific patients with heart failure and severe mitral regurgitation.

objectivesThis study sought to examine the effect of renal impairment on clinical outcomes after M-TEER using a large-scale nationwide registry in Japan.

methodsA total of 2,150 patients enrolled in the OCEAN-Mitral (Optimized Catheter Valvular Intervention) registry were divided into 3 groups according to the estimated glomerular filtration rate (eGFR) before M-TEER: normal eGFR (≥60 mL/min/1.73 m

resultsKaplan-Meier analysis revealed that the renal impairment and dialysis groups had a significantly higher incidence of MACE (survival rates at 2 years: normal eGFR, 74.2% [95% CI: 66.9%-80.1%] vs renal impairment, 63.9% [95% CI: 61.0%-66.6%] vs dialysis, 50.9% [95% CI: 38.2%-62.2%]; P < 0.001). Multivariate Cox regression analysis identified dialysis as the strongest independent predictor of MACE (HR: 1.95; 95% CI: 1.33-2.85; P < 0.001).

conclusionsRenal impairment was associated with an increased incidence of major adverse events, and dialysis was the strongest independent predictor of poor clinical outcomes after M-TEER in Asian-Pacific patients.

Indexed as

heart failuremajor adverse cardiovascular event(s)mitral regurgitationmitral valve transcatheter edge-to-edge repairrenal impairment

Identifiers

PMID39967218
PMCPMC11840231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.